DNLI
Price
$15.04
Change
+$0.09 (+0.60%)
Updated
Mar 11 closing price
Capitalization
2.18B
62 days until earnings call
PTGX
Price
$59.76
Change
+$3.81 (+6.81%)
Updated
Mar 11 closing price
Capitalization
3.67B
49 days until earnings call
Ad is loading...

DNLI vs PTGX

Header iconDNLI vs PTGX Comparison
Open Charts DNLI vs PTGXBanner chart's image
Denali Therapeutics
Price$15.04
Change+$0.09 (+0.60%)
Volume$1.75M
Capitalization2.18B
Protagonist Therapeutics
Price$59.76
Change+$3.81 (+6.81%)
Volume$2.62M
Capitalization3.67B
DNLI vs PTGX Comparison Chart
Loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PTGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNLI vs. PTGX commentary
Mar 12, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a Hold and PTGX is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Mar 12, 2025
Stock price -- (DNLI: $15.04 vs. PTGX: $59.76)
Brand notoriety: DNLI and PTGX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 154% vs. PTGX: 291%
Market capitalization -- DNLI: $2.18B vs. PTGX: $3.67B
DNLI [@Biotechnology] is valued at $2.18B. PTGX’s [@Biotechnology] market capitalization is $3.67B. The market cap for tickers in the [@Biotechnology] industry ranges from $355.07B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whilePTGX’s FA Score has 3 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • PTGX’s FA Score: 3 green, 2 red.
According to our system of comparison, PTGX is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 4 TA indicator(s) are bullish while PTGX’s TA Score has 5 bullish TA indicator(s).

  • DNLI’s TA Score: 4 bullish, 6 bearish.
  • PTGX’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, PTGX is a better buy in the short-term than DNLI.

Price Growth

DNLI (@Biotechnology) experienced а -5.71% price change this week, while PTGX (@Biotechnology) price change was +54.58% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.43%. For the same industry, the average monthly price growth was -8.50%, and the average quarterly price growth was -7.70%.

Reported Earning Dates

DNLI is expected to report earnings on May 13, 2025.

PTGX is expected to report earnings on Apr 30, 2025.

Industries' Descriptions

@Biotechnology (+0.43% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PTGX($3.67B) has a higher market cap than DNLI($2.18B). PTGX YTD gains are higher at: 54.819 vs. DNLI (-26.202). PTGX has higher annual earnings (EBITDA): 152M vs. DNLI (-496.05M). DNLI has more cash in the bank: 837M vs. PTGX (469M). PTGX has less debt than DNLI: PTGX (10.9M) vs DNLI (52.5M). PTGX has higher revenues than DNLI: PTGX (324M) vs DNLI (0).
DNLIPTGXDNLI / PTGX
Capitalization2.18B3.67B60%
EBITDA-496.05M152M-326%
Gain YTD-26.20254.819-48%
P/E RatioN/A14.13-
Revenue0324M-
Total Cash837M469M178%
Total Debt52.5M10.9M482%
FUNDAMENTALS RATINGS
DNLI vs PTGX: Fundamental Ratings
DNLI
PTGX
OUTLOOK RATING
1..100
6323
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
68
Overvalued
PROFIT vs RISK RATING
1..100
10025
SMR RATING
1..100
9121
PRICE GROWTH RATING
1..100
9236
P/E GROWTH RATING
1..100
9719
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PTGX's Valuation (68) in the Biotechnology industry is in the same range as DNLI (94). This means that PTGX’s stock grew similarly to DNLI’s over the last 12 months.

PTGX's Profit vs Risk Rating (25) in the Biotechnology industry is significantly better than the same rating for DNLI (100). This means that PTGX’s stock grew significantly faster than DNLI’s over the last 12 months.

PTGX's SMR Rating (21) in the Biotechnology industry is significantly better than the same rating for DNLI (91). This means that PTGX’s stock grew significantly faster than DNLI’s over the last 12 months.

PTGX's Price Growth Rating (36) in the Biotechnology industry is somewhat better than the same rating for DNLI (92). This means that PTGX’s stock grew somewhat faster than DNLI’s over the last 12 months.

PTGX's P/E Growth Rating (19) in the Biotechnology industry is significantly better than the same rating for DNLI (97). This means that PTGX’s stock grew significantly faster than DNLI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNLIPTGX
RSI
ODDS (%)
Bullish Trend 1 day ago
84%
Bearish Trend 1 day ago
74%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
74%
Bearish Trend 1 day ago
82%
Momentum
ODDS (%)
Bearish Trend 1 day ago
81%
Bullish Trend 1 day ago
82%
MACD
ODDS (%)
Bearish Trend 1 day ago
76%
Bullish Trend 1 day ago
88%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
82%
Bullish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
85%
Bullish Trend 1 day ago
84%
Advances
ODDS (%)
Bullish Trend 8 days ago
79%
Bullish Trend 1 day ago
79%
Declines
ODDS (%)
Bearish Trend 10 days ago
79%
Bearish Trend 16 days ago
76%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
82%
Aroon
ODDS (%)
Bearish Trend 1 day ago
83%
N/A
View a ticker or compare two or three
Ad is loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PTGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
FOREX / NAMEPrice $Chg $Chg %
CADUSD0.69N/A
N/A
Canadian Dollar - United States Dollar
EURCAD1.56N/A
N/A
Euro - Canadian Dollar
JPYCHF0.60N/A
N/A
Japan Yen - Switzerland Franc
XAGUSD32.01N/A
N/A
Silver Ounce - United States Dollar
CPVCX26.55N/A
N/A
abrdn International Small Cp C

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with RGNX. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then RGNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
+0.60%
RGNX - DNLI
54%
Loosely correlated
+1.66%
RCKT - DNLI
52%
Loosely correlated
-4.54%
NTLA - DNLI
52%
Loosely correlated
-1.64%
BEAM - DNLI
52%
Loosely correlated
+2.82%
CRSP - DNLI
51%
Loosely correlated
-2.19%
More

PTGX and

Correlation & Price change

A.I.dvisor indicates that over the last year, PTGX has been loosely correlated with CKPT. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if PTGX jumps, then CKPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PTGX
1D Price
Change %
PTGX100%
+6.81%
CKPT - PTGX
48%
Loosely correlated
+0.25%
DNLI - PTGX
41%
Loosely correlated
+0.60%
ZYME - PTGX
39%
Loosely correlated
+5.23%
REPL - PTGX
38%
Loosely correlated
+2.60%
ORMP - PTGX
37%
Loosely correlated
+4.78%
More